Country: United States
Language: English
Source: NLM (National Library of Medicine)
MINOCYCLINE HYDROCHLORIDE (UNII: 0020414E5U) (MINOCYCLINE - UNII:FYY3R43WGO)
Zydus Pharmaceuticals (USA) Inc.
MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE 45 mg
ORAL
PRESCRIPTION DRUG
Minocycline hydrochloride extended-release tablets are indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. Minocycline hydrochloride extended-release tablets did not demonstrate any effect on non-inflammatory acne lesions. Safety of minocycline hydrochloride extended-release tablets has not been established beyond 12 weeks of use. This formulation of minocycline has not been evaluated in the treatment of infections [see Clinical Studies (14)]. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, minocycline hydrochloride extended-release tablets should be used only as indicated [see Warnings and Precautions (5.11)]. This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. Minocycline hydrochloride extended-release tablets should not be used during pregnancy. If the patient becomes pregnant while taking this drug, the
Minocycline Hydrochloride Extended-release Tablets, 45 mg are grey colored, modified capsule shaped, biconvex, coated tablets, debossed with "531" on one side and plain on other side and are supplied as follows: NDC 68382-531-06 in bottles of 30 tablets NDC 68382-531-16 in bottles of 90 tablets NDC 68382-531-01 in bottles of 100 tablets NDC 68382-531-05 in bottles of 500 tablets NDC 68382-531-10 in bottles of 1000 tablets NDC 68382-531-30 in unit-dose blister cartons of 100 (10 x 10) unit-dose tablets Minocycline Hydrochloride Extended-release Tablets, 80 mg are whitish blue colored, modified capsule shaped, biconvex, coated tablets, debossed with "551" on one side and plain on other side and are supplied as follows: NDC 68382-551-06 in bottles of 30 tablets NDC 68382-551-16 in bottles of 90 tablets NDC 68382-551-01 in bottles of 100 tablets NDC 68382-551-05 in bottles of 500 tablets NDC 68382-551-10 in bottles of 1000 tablets NDC 68382-551-30 in unit-dose blister cartons of 100 (10 x 10) unit-dose tablets Minocycline Hydrochloride Extended-release Tablets, 90 mg are light yellow colored, modified capsule shaped, biconvex, coated tablets, debossed with "533" on one side and plain on other side and are supplied as follows: NDC 68382-533-06 in bottles of 30 tablets NDC 68382-533-16 in bottles of 90 tablets NDC 68382-533-01 in bottles of 100 tablets NDC 68382-533-05 in bottles of 500 tablets NDC 68382-533-10 in bottles of 1000 tablets NDC 68382-533-30 in unit-dose blister cartons of 100 (10 x 10) unit-dose tablets Minocycline Hydrochloride Extended-release Tablets, 105 mg are light blue colored, modified capsule shaped, biconvex, coated tablets, debossed with "552" on one side and plain on other side and are supplied as follows: NDC 68382-552-06 in bottles of 30 tablets NDC 68382-552-16 in bottles of 90 tablets NDC 68382-552-01 in bottles of 100 tablets NDC 68382-552-05 in bottles of 500 tablets NDC 68382-552-10 in bottles of 1000 tablets NDC 68382-552-30 in unit-dose blister cartons of 100 (10 x 10) unit-dose tablets Minocycline Hydrochloride Extended-release Tablets, 135 mg are light pink colored, modified capsule shaped, biconvex, coated tablets, debossed with "535" on one side and plain on other side and are supplied as follows: NDC 68382-535-06 in bottles of 30 tablets NDC 68382-535-16 in bottles of 90 tablets NDC 68382-535-01 in bottles of 100 tablets NDC 68382-535-05 in bottles of 500 tablets NDC 68382-535-10 in bottles of 1000 tablets NDC 68382-535-30 in unit-dose blister cartons of 100 (10 x 10) unit-dose tablets Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Keep this and all drugs out of the reach of children. Protect from light, moisture and excessive heat. Dispense in a tight, light-resistant container as defined in the USP with child-resistant closure.
Abbreviated New Drug Application
MINOCYCLINE HYDROCHLORIDE- MINOCYCLINE HYDROCHLORIDE TABLET, EXTENDED RELEASE ZYDUS PHARMACEUTICALS (USA) INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE MINOCYCLINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR MINOCYCLINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS. MINOCYCLINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1971 INDICATIONS AND USAGE Minocycline hydrochloride extended-release tablets are a tetracycline-class drug indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. (1) DOSAGE AND ADMINISTRATION The recommended dosage of minocycline hydrochloride extended-release tablets are approximately 1 mg/kg once daily for 12 weeks. (2) DOSAGE FORMS AND STRENGTHS Extended-release tablets: 45 mg, 80 mg, 90 mg, 105 mg and 135 mg (3) CONTRAINDICATIONS This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. (4) WARNINGS AND PRECAUTIONS The use of minocycline hydrochloride extended-release tablets during tooth development (last half of pregnancy, infancy, and childhood up to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). (5.1) If pseudomembranous colitis occurs, discontinue minocycline hydrochloride extended-release tablets. (5.2) If liver injury is suspected, discontinue minocycline hydrochloride extended-release tablets. (5.3) If renal impairment exists, minocycline hydrochloride extended-release tablet doses may need to be adjusted to avoid excessive systemic accumulations of the drug and possible liver toxicity. (5.4) Minocycline may cause central nervous system side effects including light-headedness, dizziness, or vertigo. Advise patients. (5.5) Minocycline may cause pseudotumor cerebri (benign intracranial hypertension) in adults and adolescents. Discontinue minocycline hydrochloride extended-rel Read the complete document